Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study

Description

Chronic obstructive pulmonary disease (COPD) is often caused by cigarette smoking, but genetic predisposition also influences COPD susceptibility. The purpose of this study is to identify genetic factors that predispose some individuals to develop COPD.

Study Start Date

July 1994

Estimated Completion Date

July 2018

Interventions

No interventions cited

Specialties

  • Internal Medicine: Pulmonology
  • Nursing: Pulmonology
  • Pulmonology: COPD

MeSH Terms

  • Lung Diseases
  • Pulmonary Disease, Chronic Obstructive

Study ID

National Heart, Lung, and Blood Institute (NHLBI) -- 1437

Status

Unknown

Trial ID

NCT01177618

Study Type

Observational

Trial Phase

N/A

Enrollment Quota

2000

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Inclusion Criteria for Early-Onset COPD Probands:
  • Early onset of COPD in individuals younger than 53 years old
  • Spirometry results that are indicative of severe COPD (FEV1 < 40% predicted)
  • Physician-diagnosed COPD Exclusion Criteria for Early-Onset COPD Probands:
  • Severe alpha-1 antitrypsin deficiency
  • Other chronic lung diseases in participants with COPD (except asthma)
  • Pregnant
  • Any previous lung surgery including lung transplant or lung reduction volume surgery (LVRS)
  • unless prior Pulmonary Function Tests are available

    Gender

    Both

    Ages

    N/A

    Accepts Healthy Volunteers

    No

    Study Locations and Contact Information (2)

    Study Location Distance Name Phone Email
    Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles None None None
    Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Cherie Maguire 617-525-2075 rechm@channing.harvard.edu

    ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.